chrisvoncsefalvay/vaers-outcomes huggingface dataset:
12:45 pm - Booster dose administered to left arm very carefully 4:00 pm - Immune system started to bog down around 4:00. 7:00 - Lips felt like they were vibrating 9:30 - pain started 10:30 - extreme body pain started& feverish 2:30 - fever broke and extreme body pain a little less 12/3/21 - Very tired and flu symptoms  Pain in left armpit - glands?, tendons ropy 12/4 - more energy, pain in armpit Continued worsening of ?autoimmune? symptoms (which were actually diagnosed 9 months later as a genetic condition called Hypermobile, Ehlers Danlos Syndrome)? pain, fatigue, brain fog, heightened allergic reactions, etc.
other zoster-related conditions; shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation, referring to a patient of unknown age and gender. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On or about 01-JAN-2011, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) for the long-term prevention of shingles and/or zoster-related conditions (strength, dose, route of administration, anatomical location, lot number, and expiration date were not reported). At the time of vaccination, the patient relied on the warning label affixed to zoster vaccine live (ZOSTAVAX), and the information relayed through the patient's healthcare provider that zoster vaccine live (ZOSTAVAX) was effective in preventing shingles on a permanent basis and did not carry any significant risk of adverse effects, which induced the patient to be vaccinated. Alternatively, on or about 01-JAN-2011, the patient's pharmacist relied on the warning label affixed to the zoster vaccine live (ZOSTAVAX) vaccine and believed that it was effective in preventing shingles on a long-term or permanent basis that it did not carry any significant risks of adverse effects. On an unknown date, reported as subsequent to the vaccination, the patient was treated for shingles and other zoster-related conditions. As a direct and proximate result of the patient's use of the zoster vaccine live (ZOSTAVAX) vaccine, the patient had and would continue suffered ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future. The outcome of shingles and ill-defined disorder were not recovered. The reporter considered shingles and ill-defined disorder to be related to zoster vaccine live (ZOSTAVAX).
PATIENT STATES THAT SHE WAS WOKEN UP WITH PAIN AND SWELLING IN HER LEFT ARM, THAT WAS APPROXIMATELY 3"X5" WITH A 1/4 " RISE. PATIENT WAS INSTRUCTED TO GET NSAIDS LIKE IBUPROFEN.
This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were unspecified. On an unknown date the patient was vaccinated with improperly stored GARDASIL 9 lot # L036301, expiration date: 20-DEC-2017 (dose, route of administration and anatomical location were not reported). The vaccine was stored in temperature between 9 to 25 degrees Celsius for 3 hours and 30 minutes. It also underwent previous temperature excursion (9 to 25 degrees Celsius) for 2 hours and 20 minutes. Digital data logger was used to detect temperature excursion. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1707USA000768: US-009507513-1707USA000770: US-009507513-1707USA000767: US-009507513-1707USA000769: US-009507513-1707USA000794.
Patient is a 41 yo woman with no PMH who presented to an  outside urgent care with left flank pain found to have a wedgelike defect in  the posterior left lower renal pole suggestive of a renal infarct.  She  underwent CTA which did not show any embolism, thrombus, dissection.  The  radiologist did note mild beading of the bilateral renal arteries, however the  radiologist at Valley View reviewed the images as well and was not as convinced.      Left renal infarct: Given suggestion of mild feeding of the bilateral  renal arteries, patient underwent CTA of the chest, head and neck which did not  show any other signs of fibromuscular dysplasia.  Echocardiogram did not have  any thrombus or decrease in function.  Patient did not have any arrhythmias on  telemetry.      Blood cultures were ordered and pending on discharge, but patient did not have  any of endocarditis      A hypercoagulable work-up including factor V Leiden, protein C, protein S,  Antithrombin, lupus anticoagulant, beta-2 microglobulin, anticardiolipin  antibodies were all sent and are pending at the time of discharge      Discussed the case with hematology at hospital: Most experts  treat with 3 months of anticoagulation other evidence is not entirely clear and  aspirin 81 mg may be a reasonable choice.  In light of the patient's lack of  insurance, decision was made to treat with 1 month of apixaban followed by 81  mg of aspirin daily indefinitely      Discharged with a short course of oxycodone 5 mg #15
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 65-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), in Sep2022 as dose 1, single (Batch/Lot number: unknown), in left arm and as dose 2, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose number unknown, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Diabetes insipitus" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (2023) Negative, notes: Tested positive for COVID after testing negative; (2023) Positive, notes: Tested positive for COVID after testing negative. Therapeutic measures were taken as a result of drug ineffective, covid-19 with Paxlovid for COVID 19 from 23Jan2023 to 27Jan2023.  Clinical information : Known allergies were reported as No.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Immediately on recieving injection the localized area around the injection site became inflammed and swollen with more than usual bleeding following the injection. Patient was monitored and recieved a cold compress and returned to work after approximately 15 minutes. Patient returned complaining of still feeling off approximately 2 hours later, patient stated she was feeling dizzy and lightheaded as well as feeling tingly in the injection arm. Patient was given Benadryl and reccommended to take ibuprofen for pain which she did. The following day 10/14/2014 patient developed a rash on her upper body and head and went to the emergency room for treatment.
GONNA DIE; HURTING AT VACCINATION SITE; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 02-APR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot number. No concomitant medications were reported. On 02-APR-2021, the patient experienced hurting at vaccination site. On an unspecified date, the patient experienced gonna die. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the hurting at vaccination site and gonna die was not reported. This report was non-serious.
c/o fever w/red, swollen vax site;1 vesicle noted on soft palate, 1 on tongue, 2 on neck;large blotchy light red area on lt triceps (10.5cm x 10cm); appears to have indurated area;?early lesions, non tender when palpated;T100.8 oral,
Patient said her arm was swollen and she was unable to lift her arm up for 5 days.
The patient did not experience any adverse events that I am aware of.  The patient was administered a Pfizer bivalent vaccine that was improperly stored and administered past the beyond use date.
Long-term  blood pressure variation (swings).  I monitor my blood pressure regularly because of adverse reactions to several drugs, including oral birth control pills and medications to control depression. After receiving my fourth COVID vaccine, which I was told was the Moderna bivalent but which was apparently not available then, I began having large swings in blood pressure after years of stability at 120/70 (except for medication-induced elevation).  For the most part the BP was elevated, anywhere from 140s/80s to 160s/90s, but it would also dip low.  In the fall (~Oct, 2022 I began reducing my nortriptylene and eventually got off it entirely, with no reduction in blood pressure swings.  I began lisinopril (5 mg/day, now increased to 7.5 mg/day, taken at bedtime) which was previous successful in reducing SSRI-induced elevated BP, and this has reduced BP to, in general, 130s/80s, but I still experience wide swings, mostly elevations, especially towards the end of the day as the lisinopril wears off.
12 hours after receiving my 2nd dose of the HepB vacc. I woke up with a severe burning sensation down the injected arm and across my chest and into my abdomen. I also had uncontrollable vomiting and a high fever. I was treated with in the emergency room and released to follow up with my physician.
Patient seen by MD on 5/3/07, 5/5/07 and 5/8/07 for raised, erythematous, blanching rash on neck, torso and arms. No other symptoms. 5/10/07 follow up phone call, pt reported rash had not resolved, but was not worsening.
Site: Bruising at Injection Site-Mild, Site: Itching at Injection Site-Medium, Site: Redness at Injection Site-Severe, Systemic: Allergic: Itch (specify: facial area, extremeties)-Medium, Systemic: Allergic: Rash (specify: facial area, extremeties)-Severe, Systemic: Allergic: Rash Generalized-Severe, Systemic: HEAT AT INJECTION SITE-Severe, Additional Details: The rash is spreading and is containing  a lot of heat. Initially, the rash started right after injection but has worsen of a week since the injection.
Resident received 5th dose of vaccine - had received doses 12/30/20, 1/20/21, 11/4/21, 5/25/22 and 8/10/22.  Resident monitored, no adverse reaction noted
This case was reported by a health professional and described a 31 year old male who did not respond to the hepatitis B vaccine recombinant (Engerix-B) immunization series.  The pt's medical history, concurrent conditions, and concurrent medications were not reported.  The pt received injections of Engerix-B on 08/23/01 (Lot # ENG5235A4), 09/25/01 (Lot # ENG5239A4) and 05/07/2002 (Lot # ENG5242A4).  On 04/23/03, a hepatitis B surface antibody titer measured less than 2.0.
16  self-registered for booster vaccination with parental consent via guardian present in the building. Pt proceeded to the vaccine station where he received a Moderna booster dose. Of note he received primary series of Pfizer vaccines with 1st dose Lot # ER 8733 on 4/7/2021 and 2nd dose Pfizer, Lot # EW0164 on 4/28/2021. Pt was notified of the inadvertently administered vaccine for his age. Present guardian was also notified of the same and his mother was notified of the event via telephone call at 1854h. Pt was observed from time of vaccination administration until 1910h. No untoward signs or symptoms were noted during the time of observation.
Received DTaP on 02/23/05. Patient complaint from mom, 02/24/05, describing a large red, warm hard area to left arm. Large 4 x 4 red, warm area to the left shoulder. Treated with compresses and Motrin. Instructed to go to urgent care that afternoon and to the family doctor on 02/25/05. Was started on Keflex for 7 days for cellulitis.
Started to get a prolonged headache, body feeling weak and achy, slight fever of 99.8,  tired, lack of appetite and nauseated.
Chickenpox rash. On 4/25/06, given Zovirax Susp 2 tsp po qid x 5 days.
I had constant headache, bone pain, my arm swelled up and got red around the injection site. I also had sinus pain, my muscles hurt so bad I could barely walk. My skin felt crawly. My eyes were swollen, my glands in my neck were swollen. I was physically weak and extremely tired. I had no stamina whatsoever. I had sharp pain in both ears off and on. My throat felt really swollen and dry. I had bleeding around my eyes and on my skin. Everything lasted for over a month. There was a spot in my right arm close to my elbow that was swollen about the size of a dime. It kept getting tender and swollen. I went to the doctor and ended up having surgery in Jan or Feb of 2022 and it turned out to be a blood clot.
Menstrual period cycle is now reduced from approximately 30 days to approximately 18 days
severe erythema lt deltoid area;Ibuprofen, warm compresses x 3 days;
Information has been received from a former clinical investigator concerning a cluster of approximately 114-115 patients from a original group of approximately 128 patients, of unspecified age and sex who on an unspecified date were vaccinated with a dose of MMR II (route and lot # unknown) and on an unspecified date they experienced mumps. The physician reported that he has done some laboratory work to confirm the diagnosis of mumps in a few children and he did not find any children who were IgM positive for mumps, but most were IgG positive. The physician stated that most children had a parotid gland swelling. It was unknown is the patients sought medical attention. At the time of the report the patient's outcome was unknown. This is one of several reports from the same source. Additional information has been requested.
fatigue and tiredness; arm soreness; flu like symptoms; feeling sick; redness on arm; rash on upper arm; itching on upper arm; This case was reported by a consumer via call center representative and described the occurrence of fatigue in a 69-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles.   On 22nd April 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than a year after receiving Shingrix, the patient experienced fatigue, pain in arm, influenza-like symptoms, feeling unwell, erythema of extremities, rash and itchy upper limbs. On an unknown date, the outcome of the fatigue, pain in arm, influenza-like symptoms, feeling unwell, erythema of extremities, rash and itchy upper limbs were recovered/resolved.   It was unknown if the reporter considered the fatigue, pain in arm, influenza-like symptoms, feeling unwell, erythema of extremities, rash and itchy upper limbs to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported but it could be 67 or 68 years. The patient experienced fatigue, tiredness, arm soreness, flu like symptoms, feeling sick. She also experienced redness, itching and rash in the whole upper part of the arm where she got the vaccine. She said that her arm soreness and itching lasted about 3 days. Other symptoms cleared up in about a week. The reporter did not consent to follow-up.
Started feeling feverish, chills, nauseous 14 hours after 2nd dose. Extremely achy, mild fever for 20 hours total.
Vaccine administered approximately 345 pm on 1/24/12. Pt. called 1/25/12 in A.M. & stated she developed hives & itching during "middle of night (woke her up from sleep)". Symptoms improved over course of day. No other symptoms.
Information has been received from a health professional concerning a 17 year old female who on 11-OCT-2007, was vaccinated with her first dose of Gardasil vaccine. On 12-OCT-2007, the patient experienced a rash on legs and abdomen. The patient sought unspecified medical attention and her outcome is unknown. The patient was prescribed, by the physician, Benadryl to treat the rash. Additional information has been requested.
Headache, fever of 101,  aches and pains ( including hair roots hurting),  nausea, and exhaustion
This spontaneous report as received from a certified medical assistant refers to a patient of unknown age and gender. On 25-AUG-2014 the patient was vaccinated with a dose of VARIVAX (Merck) (dose, units, route of administration, lot# and expiration date not provided) which was exposed to a supported temperature excursion on 15-AUG-2014. No adverse events had been observed or reported. This is one of several reports from the same reporter. Additional information has been requested.
Patient was given an undiluted vaccine and a larger dose (0.3mg) than he should have received.
36 y/o Male developed chest tightness and SOB approx. 45 min. after recieving Anthrax vaccine #1. Symptoms progressed throughout the day, described as "flu-like symptom", H/A,Myalgia, afebrile. Approx. 24 hrs later developed diffuse rash torso,arms&legs.  Evaluated and admitted to hospital.  Elevated immune complexes and absent reflexes noted on clinical exam.  Evaluated by neurologist, DX. with mild Guillian-Barre. The 60 day follow up received on 9/17/03 states pt still c/o persistent symptoms of muscle weakness, joint pain, fatigue and migraine headaches. He was admitted on 9/3/03 for severe migraine headaches and chest pain x 1 day. He is currently followed by rheumatology and neurology.
Approximately 30 hours after Td vaccination, pt started running  high fever with severe chills and body ache. Also, at the time of reaction, a lump developed at injection site. Pt took 2 doses of 3 aspirin that evening without any relief. Within 24 hours from onset of symptoms, they had all subsided.
STIFFNESS OF THE SUBLINGUAL ONE; PRESSURE IN THE TONGUE; PROGRESSIVE ENLARGEMENT OF THE SUBMANDIBULAR SALIVARY GLAND BOTH ON THE LEFT AND RIGHT/IT GROWS EVEN LARGER WHEN CONSUME FOOD AND DRINKS; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on OCT-2021 for covid-19 prophylaxis. The batch number was not reported and has been requested. No concomitant medications were reported. On 2021, the patient experienced progressive enlargement of the submandibular salivary gland both on the left and right/it grows even larger when consume food and drinks. On an unspecified date, the patient experienced stiffness of the sublingual one, and pressure in the tongue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from progressive enlargement of the submandibular salivary gland both on the left and right/it grows even larger when consume food and drinks, and stiffness of the sublingual one, and the outcome of pressure in the tongue was not reported. This report was non-serious.
Pt received second dose of pfizer at  clinic. Experienced H/A while waiting 30 minutes after dose administered. BP taken 210/110. Pt reports has hx HTN, has not taken medication in greater than a week. EMS assessed pt- sent to hospital  for further evaluation
Information has been received from a physician concerning a 13 year old (also reported as 10 year old) male who on 11-DEC-1998 and 20-NOV-2001 was vaccinated with the first and second dose of MMR II respectively (route, site and lot number not reported). On 02-JAN-2010 the patient experienced mumps. The patient was diagnosed on 04-JAN-2010. The patient parotitis was on right side and was afebrile. On 04-JAN-2010, the first blood work was done which revealed serum IgM <1:10 and serum IgG 7.57. The outcome for mumps was not reported. This is one of several reports from the same source. Additional information has been requested.
Information has been received from a healthcare worker (physician assistant) referring to a patient of unknown age and gender. The patient's medical history, concurrent condition therapy were not reported. On 20-MAY-2015, the patient was vaccinated with a dose of RECOMBIVAX HB, lot # J012567, expiration date 30-JAN-2016 (dose and route not reported), which was improperly stored. no adverse effects were reported. Additional information has been requested.
Right eye droopy, watery, red....fever 101.2 r ear pain, no stiff neck at this time.
Excruciating pain in left leg, with left knee pain so severe that it is very difficult to walk.
This is a spontaneous report from a contactable consumer. A 69-year-old female consumer (patient) reported for herself that she received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on 19Apr2021 on left arm as dose 2, single for COVID-19 immunization. The patient's medical history, concomitant medications and information about investigation assessment were not reported. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on an unknown date, as dose 1, single for COVID-19 immunization and experienced no adverse events. On an unknown date in Apr2021 the patient complained that her left arm was continuously feeling as if it had gone to sleep and had ants walking down her arm after the second dose of the Pfizer Covid-19 vaccine. Caller asked if this was a reported side effect of the Pfizer Covid-19 vaccine. Caller asked how these symptoms would resolve. The event outcome was unknown. The lot number for the vaccine, [BNT162B2], was not provided and would be requested during follow up.
About 2 weeks after my vaccine, I got a high fever and my abdomen started really hurting. I went to my PCP and was told that I had a UTI. He gave me a prescription for phenazopyridine and it went away.
The day after immunization, left arm developed redness, swelling, hot to touch, area approx 2" x 1 1/2". Advised Tylenol, Benadryl and cool compress to area.
Patient received a expired vaccine 16-Apr-2022; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received a expired vaccine 16-Apr-2022) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007J21-2a) for COVID-19 vaccination.     The patient's past medical history included COVID-19 virus test positive.    On 22-Apr-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received a expired vaccine 16-Apr-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received a expired vaccine 16-Apr-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication information was not provided by the reporter.  Treatment information was not provided by the reporter.
3/29/2021 05:30am intermittent electrical pain in limbs 3/29/2021 01:30pm Left axillary pain and swelling that lasted for days  Fever, chills, sweats, body aches persisted from 3/27/21 through 3/30/2021.